Pfizer Inc. Strategic Analysis: Governance, SWOT, and Growth
This paper presents a comprehensive strategic analysis of Pfizer Inc., one of the world's largest research-based pharmaceutical companies. It examines Pfizer's current business situation, including its three primary business units and major product portfolio. The paper reviews corporate governance structures, including board composition and the Executive Leadership Team. It then analyzes the external environment for opportunities (such as anti-viral and vaccine markets) and threats (including generic competition and patent challenges), followed by an internal assessment of strengths and weaknesses. The paper concludes with strategic alternatives, implementation steps, and evaluation mechanisms to guide Pfizer's continued growth and competitiveness.
- Current Situation: Pfizer's size, products, and business units
- Corporate Governance: Board structure and executive leadership
- External Environment: Opportunities and Threats: Market opportunities and competitive threats
- Internal Environment: Strengths and Weaknesses: Compliance strengths and packaging strategy
- Analysis of Strategic Factors: Key strategic objectives outlined
- Strategic Alternatives and Recommended Strategy: Recommended actions for growth and protection
- Implementation and Evaluation: Acquisitions and performance monitoring
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Follows a clear, structured strategic-analysis framework (situation → governance → external/internal environment → strategy → implementation → evaluation) that mirrors a standard business case format.
- Supports claims with direct citations from Pfizer's SEC Form 10-K, investor presentations, and trade publications, lending credibility to the analysis.
- Balances qualitative discussion with concrete data points — revenue figures, R&D budget, environmental expenditures — giving the analysis measurable grounding.
Key academic technique demonstrated
The paper demonstrates effective use of the SWOT framework integrated within a multi-section strategic analysis. Rather than treating SWOT as a standalone exercise, the author embeds strengths, weaknesses, opportunities, and threats within distinct environmental sections and then synthesizes them into actionable strategic alternatives — showing how internal capabilities can be matched to external opportunities while mitigating identified threats.
Structure breakdown
The paper is organized into eight numbered sections: (I) Current Situation establishes company background and product portfolio; (II) Corporate Governance covers board structure and leadership; (III) External Environment identifies market opportunities and competitive threats; (IV) Internal Environment assesses strengths and weaknesses; (V) Analysis of Strategic Factors synthesizes key objectives; (VI) Strategic Alternatives proposes concrete recommendations; (VII) Implementation discusses recent acquisitions as evidence of execution capacity; and (VIII) Evaluation and Control addresses performance monitoring mechanisms.
Current Situation
Pfizer Inc. is reported to be "one of the biggest players in what is widely considered the most influential industry in Washington: pharmaceutical manufacturers" (Center for Responsive Politics, 2009). Pfizer is one of the five largest pharmaceutical companies worldwide and produces several of the best-selling prescription drugs on the market, including Viagra. The company has maintained continuous growth and purchased Warner-Lambert in 2000, then announced it would purchase Pharmacia in 2002 (Center for Responsive Politics, 2009).
Pfizer has undergone "a period of extremely rapid growth resulting from the commercial success of products including Viagra, Lipitor, and Celebrex. This aggressive growth strategy, enabled through mergers and acquisitions, was designed to achieve the scale required to gain synergies, invest in costly technologies, and spread the enormous risk of the drug development process. Yet size can itself become an impediment to the agility and flexibility which are critical to lasting business success. Retaining these characteristics can be a serious challenge for successful companies" (Tradeline, 2004).
The Global Operations within the R&D division of Pfizer Inc. has responded to this challenge by "building a foundation for the future based on best practices from the companies of which it is now comprised" (Tradeline, 2004). The company is now "the world's largest research-based pharmaceutical company" and is organized into three primary business units:
1) Human health care (developing, manufacturing, and marketing prescription drugs);
2) Animal health care; and
3) Consumer health care (over-the-counter drugs). (Tradeline, 2004)
Pfizer Global Research and Development (PGRD) is part of the human health care business unit, which has major Research & Development sites in the U.S., Europe, and Asia producing "leading products in 14 therapeutic categories" with a Research and Development budget of more than $7 billion (Tradeline, 2004).
Corporate headquarters for Pfizer Inc. are located in New York, NY. Research and Development divisions are located in Connecticut, England, California, Missouri, and Massachusetts. Pfizer is listed on the New York Stock Exchange as PFE and on the London Stock Exchange as PFZ. 2008 revenues for Pfizer Inc. are stated at $48.3 billion.
Products manufactured by Pfizer Inc. include the following:
Key Pharmaceutical Products: Aricept®, Aromasin®, Caduet®, Camptosar®, Celebrex®, Chantix™, Detrol/Detrol LA®, Eraxis®, Genotropin®, Geodon/Zeldox®, Lipitor®, Lyrica®, Norvasc®, Rebif®, Relpax®, Revatio®, Spiriva®, Sutent®, Vfend®, Viagra®, Xalatan/Xalacom®, Zmax®, Zoloft®, and Zyvox®.
Key Animal Health Products: Draxxin®, Excede®, Naxcel/Excenel®, RespiSure/Stellamune®, Dectomax®, Rimadyl®, Revolution/Stronghold®, Clavamox/Synulox®, BoviShield®, Lutalyse®, Slentrol®, Cerenia®, Convenia®, and Improvac®.
Corporate Governance
Board of Directors
There are presently 14 individuals on the Board of Directors for Pfizer Inc., with an average director age of 65 years. There are 12 independent directors on the Board, and the board includes a Lead Independent Director, an Independent Audit Committee, and an Independent Compensation Committee. The Board meets more than 13 times per year and holds annual board elections. Corporate Governance Guidelines are approved by the Board of Directors, and outside directors hold meetings without management present. The Board conducts an annual self-evaluation and an annual review of its independence, and requires key committee self-evaluations. The Board maintains board orientation and education programs, a corporate compliance program, a disclosure committee for financial reporting, and is governed by a Code of Ethics.
Top Leadership
The Executive Leadership Team (ELT) is Pfizer's senior-most leadership, management, and decision-making body. This team brings together the top leaders at Pfizer Inc. "to focus on major financial, strategic, and operational decisions for the company." According to Pfizer Inc., "to best position our business for continued success, the ELT is focused on working with agility, speed, and collaboration to ensure that opportunities are rapidly seized and challenges immediately perceived and addressed" (Pfizer Inc., 2009).
Pfizer states that it has "created an integrated, streamlined, 'one company' organizational structure in which line management, functional experts, and a few centers of excellence work in close collaboration to advance our business objectives. With this structure, we are aligned to meet the needs of our markets and customers, and rapidly capitalize on opportunities to advance our business by increasing support for successful new medicines, forging partnerships with key customers, entering into co-promotion and licensing agreements, investing in new technologies to add value to our core product offerings, and acquiring new products and services from outside the company" (Pfizer Inc., 2009).
Create your account
Always verify citation format against your institution’s current style guide requirements.